| Overview |
| bs-2584R |
| IGSF8 Polyclonal Antibody |
| WB, ELISA, FCM, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human |
| Mouse, Rat, Cow, Pig, Horse |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from mouse IGSF8 |
| Polyclonal |
| #REF! |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4_. Store at -20_ for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 140559 |
| Q8R366 |
| Cell membrane |
| PGRL; EWI-2; KCT-4; ESTM34; R75384; AA033172; AU041109; Immunoglobulin superfamily member 8; IgSF8; CD81 partner 3; Glu-Trp-Ile EWI motif-containing protein 2; Keratinocyte-associated transmembrane protein 4; Prostaglandin regulatory-like protein; CD316; Ewi2; Kct4 |
| May play a key role in diverse functions ascribed to CD81 and CD9 such as oocytes fertilization or hepatitis C virus function. May regulate proliferation and differentiation of keratinocytes. May be a negative regulator of cell motility: suppresses T-cell mobility coordinately with CD81, associates with CD82 to suppress prostate cancer cell migration, regulates epidermoid cell reaggregation and motility on laminin-5 with CD9 and CD81 as key linkers. May also play a role on integrin-dependent morphology and motility functions. May participate in the regulation of neurite outgrowth and maintenance of the neural network in the adult brain. |
| Application Dilution |
| WB |
1:300-5000 |
| ELISA |
1:500-1000 |
| FCM |
1:20-100 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |